title: Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity.
abstract: A 45-year-old woman presented with a metastatic breast carcinoma and was treated with capecitabine, oral vinorelbine and trastuzumab combination therapy. The initial echocardiogram and the ECG were considered normal. She began treatment with 3-weekly cycles of the combination therapy. After the fourth dose of capecitabine, she presented with severe chest and arm pain, which was responsive to nitroglycerine spray. ECG at admission demonstrated tachycardia with ST-segment elevation suggesting ischemia. The clinical symptoms returned to baseline after a few hours and within 24 h the ECG showed inverted T in leads V3-V6. Cardiac ultrasonography revealed hypokinesia in the left ventricle without segmentary hypokinesia, with mildly reduced global systolic function, which normalized 1 week later. Two weeks later, she was rechallenged with capecitabine. After the fourth dose, the patient developed chest pain. ECG showed infero-apico-lateral injury, which normalized after administration of nitrates, nicorandil and verapamil and discontinuation of capecitabine. This case suggests that capecitabine can lead to the cardiotoxicity characteristic of other fluoropyrimidines. Therefore, it is important to inform patients about the risk of angina-like chest pain, to stop treatment immediately if symptoms occur, and to monitor the patient in hospital. Fluoropyrimidine rechallenge should be avoided because of the risk of ischemic event or sudden death.
authors.affiliation: Department of Oncology, CHU Dupuytren, Limoges, France. valerie.lebrun@chu-limoges.fr
authors.forename: Valérie
authors.initials: V
authors.lastname: Le Brun-Ly
authors.forename: Jean
authors.initials: J
authors.lastname: Martin
authors.forename: Laurence
authors.initials: L
authors.lastname: Venat-Bouvet
authors.forename: Nicole
authors.initials: N
authors.lastname: Darodes
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Labourey
authors.forename: Dominique
authors.initials: D
authors.lastname: Genet
authors.forename: Nicole
authors.initials: N
authors.lastname: Tubiana-Mathieu
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D000069287:Capecitabine; D002637:Chest Pain / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004562:Electrocardiography; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D017202:Myocardial Ischemia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D005996:Nitroglycerin / Q000627:therapeutic use; D011379:Prognosis; D000068878:Trastuzumab; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003841:Deoxycytidine; D014747:Vinblastine; D000069287:Capecitabine; D005996:Nitroglycerin; D000068878:Trastuzumab; D000077235:Vinorelbine; D005472:Fluorouracil